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Background. Sibjeondaebo-tang (SJDBT) has been used to treat diverse disorders including neuropsychiatric disabilities in
traditional Korean medicine. Objective. The present study aims to investigate the potential eﬀects of SJDBT on neuroprotection
against Aβ peptide-induced damage using in vitro culture and in vivo rat brain systems. Materials and Methods.P C 1 2c e l lv i a b i l i t y
was analyzed by MTT assay, and neurite arborizations and caspase 3 protein signals in cultured PC12 cells and in vivo cortical
neurons were analyzed by immunoﬂuorescence staining. Phospho-Erk1/2 protein was analyzed by immunoﬂuorescence staining
andwesternblotanalysis. Results.InPC12cells,atrophiedcellbodyandreducedneuriteextensionbyAβ treatment were recovered
by SJDBT treatment. Caspase 3 protein signals were increased in Aβ-treated PC12 cells, but SJDBT treatment decreased apoptotic
celldeath.Caspase3activationincorticalneurons,whichwasinducedsimilarlybyAβtreatment,wasreducedbySJDBTtreatment.
Furthermore, phospho-Erk1/2 protein levels, which had been decreased by Aβ treatment, were elevated in the cortical neurons by
SJDBT treatment. Conclusion. These data show that SJDBT may play a role in protecting from damages induced by Aβ in neuronal
tissue and further suggest that SJDBT can be explored as the potential therapeutic target for AD treatments in human.
1.Introduction
Alzheimer’s disease (AD) is the neurodegenerative disease,
which is most common in elderly individuals throughout
the world, particularly in the developed countries [1].
Extensive studies for the last several decades have made
remarkable progress in understanding pathophysiological
b a s i so nA D[ 2, 3]. Accumulation of β amyloid (Aβ)p e p t i d e
and formation of neuroﬁbrillary tangles are the hallmark
of AD brain in human. Thus, secretase enzyme that is
involved in the processing of Aβ peptide from amyloid
precursor protein (APP) is one of the major targets for AD
study [4]. Aβ aggregates can alter synaptic transmission, and
large aggregates are known to be toxic to neurons [5]. In
addition, numerous studies using cultured cells showed that
the treatment of Aβ peptide induced cell death even with a
lowconcentration,suggestingthatAβ peptidemoleculeitself
may act as a trigger inducing cell death pathway [6–8]. Thus,
Aβ peptide is the major target for mechanistic studies on AD
in vivo and in vitro systems.
Sibjeondaebo-tang (SJDBT) is a noted prescription in
(DongEuySuSeBoWon) [9], which describes the concept of
“Sasang Constitutional Medicine”. The basic theory of Sasang
Constitutional Medicine consists of four types: Taeyangin,
Tae-eumin, Soyangin,a n dSoeumin.E a c ho fSasang Con-
stitutional types classiﬁed by similar patterns has diﬀerent
characteristics, so there are diﬀerent patterns of diseases
and treatment methods for each type. It was suggested
that the proper therapy for Soeumin, for instance, is to
keep one’s body warm and strengthen the blood and qi,
because their blood and qi are weak and stagnant [10].
Lee [9] showed that SJDBT is applicable to treat Soeumin
exterior diseases, because it might reinforce the healthy qi
to individuals who are lacking qi due to the pathogenic
exposure or chronic disease [11]. Consistent with this
notion,onerecentstudyhasdemonstratedthatSJDBTmight2 Evidence-Based Complementary and Alternative Medicine
participate in the replenishment of declined energy and
cholinergic neurotransmitter synthesis in the mouse cerebral
cortex with memory impairment [12].
In the present study, possible protective eﬀects of SJDBT
were investigated in cultured PC12 cells and Aβ-injected
mouse. Our data indicate that SJDBT is eﬀective to a certain
level as a protective agent against Aβ peptide-mediated
toxicity in neuronal cells.
2.MaterialsandMethods
2.1. Drugs and Chemicals. SJDBT prescription used in
the present study is composed of equal amounts of the
following herbal ingredients: Ginseng Radix (the manufac-
ture’s serial number: BH0601, production area: Geumsan-
gun, Chungnam, Korea), Cynanchi Wilfordii Radix (the
manufacture’s serial number: BH0816, production area:
Yeongcheon-si, Gyeongbuk, Korea), Cinnamomi Cortex Inte-
rior (the manufacture’s serial number: SR-0033-10, pro-
duction area: Vietnam), Astragali Radix (the manufac-
ture’s serial number: BH0130, production area: Jecheon-
si, Chungbuk, Korea), Atractylodis Macrocephalae Rhizoma
(the manufacture’s serial number: BH0715, production area:
Yeongcheon-si, Gyeongbuk, Korea), Angelicae Gigantis Radix
(the manufacture’s serial number: BH0615, production area:
Pyeongchang-gun, Gangwon, Korea), Cnidii Rhizoma (the
manufacture’s serial number: BH0801, production area:
Yeongyang-gun, Gyeongbuk, Korea), Paeoniae Radix Alba
(the manufacture’s serial number: BH1030, production
area: Jinju-si, Gyeongnam, Korea), Citri Pericarpium (the
manufacture’sserialnumber:BH1210,productionarea:Jeju-
do, Korea),G l y c y r r h i z a eR a d i x(the manufacture’s serial
number: HPL220C-00608, production area: China),Z i n -
giberis Rhizoma Recens (the manufacture’s serial number:
BH0910, production area: Muju-gun, Jeonbuk, Korea), and
Zizyphi Fructus (the manufacture’s serial number: BH1205,
production area: Gyeongsan-si, Gyeongbuk, Korea).
The drug was obtained from Oriental Medical Hospital
of Daejeon University Daejeon, Korea. SJDBT (45g dry
weight) was resuspended in 1L of water, heat extracted
for 3hrs, and ﬁltered three times. The ﬁltered ﬂuid was
distilled using the rotary vacuum evaporator (B¨ uchi 461,
Eyela, USA). Concentrated solution was frozen at −70◦Cf o r
4hrs and freeze dried for 24hrs. The product for SJDBT
was 14.7g, with 29.2% yield from the initial raw materials.
The product was kept at 4◦C and dissolved in water. The
stock solution (10mg/mL in phosphate buﬀered saline) was
stored at −20◦C and used for experiment by diluting with
physiological saline solution.
β-amyloid peptide was purchased from Sigma-Aldrich
(USA), dissolved in H2Ot o1m M ,a n dk e p ta t−20◦C until
use. Galantamine triethiodide (Sigma, USA), a competitive
reversible inhibitor of acetylcholinesterase (AChE) was also
purchased from Sigma-Aldrich and diluted with H2Ot o
concentrations of 0.9 mg/mL and kept at −20◦C, freezer
until use.
2.2. Experimental Animals. Albino mice (7–9-week old,
Samtago, Korea) were used in the present study. Animals
were placed in an animal room with regulated temperature
(22◦C), 50% of humidity, and 12-hr-light and 12-hr-dark
cycle. They were allowed to eat commercial rat chow
(Samyang Co., Korea) and drink water ad libitum.A l l
procedures were in strict accordance with the US guidelines
(NIH publication no. 85-23 revised in 1985) for the care and
use of laboratory animals and approved by the Committee
onUseofLiveAnimalsforTeachingandResearchatDaejeon
University.
2.3. PC12 Cell Culture. PC12 cells were cultured in DMEM
(GIBCO,USA)supplementedwith5%FBS,5%horseserum,
and 1% penicillin/streptomycin at 37◦C incubator supplied
with 5% CO2. Cells were grown at 75cm2 ﬂask (SPL, Korea)
for 3 days and transferred into a new medium. Cells were
washed with phosphate buﬀered saline (PBS) and treated
with trypsin-versene solution (Lonza, USA) at 37◦Cf o r
5min for trituration. Detached cells were suspended with
DMEM containing 5% FBS and 5% horse serum, plated
into a new culture ﬂask with a 1:4 dilution, and incu-
bated at a CO2 incubator. For immunoﬂuorescence staining
experiments, cells (1 × 105 per coverslips) were usually
cultured on the coverslips precoated with poly-L-ornithine
(0.1mg/mL, Sigma, USA) and laminin (0.02mg/mL, Collab-
orate Research, USA) overnight at room temperature.
2.4. MTT Assay. PC12 cell viability was assayed by
reduction of MTT [3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyltetrazolium bromide] reagent. Cells (1 × 105/well)
were plated in 96-well plate. Cells were treated with 10μM
of Aβ peptide and with diﬀerent concentrations of 0.3, 0.5,
and 1.0mg/mL of SJDBT for 24hrs. Then, the cells were
treated with MTT solution for 4hrs, and optical density was
measured using spectrophotometer at 570nm. Cell viability
w a sm e a s u r e da sf o l l o w s :
Cell viability (%)
=
optical density of cells treated with drugs
optical density of cells treated with saline vehicle
× 100.
(1)
2.5. Immunoﬂuorescence Staining and Hoechst Nuclear Stain-
ing. For immunoﬂuorescence staining, cells or tissues on
the coverslips were ﬁxed with 4% paraformaldehyde 4%
sucrose in PBS at room temperature for 40min, permeabi-
lized with 0.5% Nonidet P-40 in PBS, and blocked with
2.5% horse serum and 2.5% bovine serum albumin for
4hrs at room temperature. Cells on the coverslips were
incubated with primary antibody, washed with PBST (PBS
plus 0.1% triton X-100) 3 times for 10min each, incubated
withﬂuorescein-goatanti-mouse(1:400dilution,Molecular
probes, USA) or rhodamine-goat anti-rabbit secondary
antibodies (Molecular probes) in 2.5% horse serum and
2.5% bovine serum albumin for 1hr at room temperature,
and cover-slipped with gelatin mount medium. For some
experimental purpose, Hoechst staining reaction for nuclear
visualization was performed between washing steps after
secondary antibody reaction. Tissue sections were treatedEvidence-Based Complementary and Alternative Medicine 3
with 25μg/mL of Hoechst33258 in 0.1% triton X-100 in
phosphate-buﬀered saline solution (PBST) for 10min. The
secondary antibody reaction was performed in a dark place.
The merged images were produced by layer blending mode
options of the Adobe Photoshop (version 5.5). The primary
antibodies were phospho-Erk1/2 kinase antibody (1:800,
CellSignaling,USA),cleavedcaspase3antibody(1:500,Cell
Signaling), and monoclonal antineuroﬁlament 200 (1:400,
Sigma-Aldrich).
2.6. Western Blot Analysis. Cell or tissue lysates were washed
with ice-cold PBS and sonicated under 50–200μLo ft r i t o n
lysis buﬀer (20mM Tris, pH 7.4, 137mM NaCl, 25mM β-
glycerophosphate, pH 7.14, 2mM sodium pyrophosphate,
2mM EDTA, 1mM Na3VO4, 1% triton X-100, 10% glycerol,
5μg/mL leupeptin, 5μg/mL aprotinin, 3μM benzamidine,
0.5mMDTT ,and1mMPMSF).Protein(15μg)wasresolved
in 12% SDS polyacrylamide gel and transferred to immo-
bilon polyvinylidene diﬂuoride (PVDF) membranes (Milli-
pore, Bedford, USA). Blots were blocked with 5% nonfat
dry milk in PBST (17mM KH2PO4,5 0 m MN a 2HPO4,
1.5mM NaCl, pH 7.4, and 0.05% Tween-20) for 1hr at room
temperature and then incubated overnight at 4◦Ci n0 . 1 %
triton X-100 in PBS plus 5% nonfat dry milk containing
antibodies. Protein bands were detected using the Amer-
sham ECL kit (Amersham Pharmacia Biotech, Piscataway,
USA), with horseradish peroxidase-conjugated secondary
goat anti-rabbit or goat anti-mouse antibodies (Transduc-
tion Laboratories, Lexington, USA). Relative intensities of
the protein bands were analyzed by autoradiography. The
antibodies used in the present study were phospho-p44/42
Erk1/2 kinase antibody (1:4,000, cell signaling), p44/42
Erk1/2 kinase antibody (1:4,000, cell signaling), and cleaved
caspase-3 antibody (1:1,000, cell signaling).
2.7. Aβ-Administered Mouse Model. Albino ICR mice were
randomly assigned into (i) normal group, (ii) Aβ peptide-
treated control group, (iii) positive control group treated
with Aβ peptide plus galantamine, and (iv) experiment
grouptreatedwithAβ peptideandSJDBT.5μLofAβ peptide
(200pmol) was microinjected using the glass capillary
connected to picoinjector (Harvard Instrument, USA) into
the lateral ventricle (0.5mm posterior to bregma, 1.5mm
lateral to midline, and 2.5mm ventral to the brain sur-
face) bilaterally. SJDBT extract (400mg/kg) was orally (Po)
administered when Aβ peptide was given, and 8 days after
Aβ treatment, galantamine (3mg/kg) was administered (Ip)
on a daily basis for 3 days. The brain was then dissected, and
coronalsections (20μm)werepreparedusingthecryostatfor
histological analysis.
2.8. Microscopic Analysis. Images from immunoﬂuorescence
staining were analyzed by ﬂuorescence microscope (Nikon,
Japan), and real-time images of cultured cells were analyzed
by phase-contrast microscope. The images were captured
andtransferredintothecomputersoftware(ACT-1).Merged
images were analyzed under the image blend mode of the
Adobe Photoshop software (version 5.5).
2.9. Statistical Analysis. Data were presented as mean ±
standard error of mean (SEM). A StatView512+ computer
software was used for statistical analysis by Student’s t-test.
Statistically signiﬁcant diﬀerences were reported as P<0.05,
P<0.01, or P<0.001 (see Figure 1(a)).
3. Results
3.1. Eﬀects of SJDBT on Aβ-Treated PC12 Cells. To determine
possible neuroprotective activity of SJDBT in PC12 cells
treated with Aβ peptide, cell survival was measured by MTT
a s s a y .T h el e v e l so fc e l ls u r v i v a l ,w h e nt r e a t e dw i t hA β pep-
tide,werestronglydecreasedasmuchas40%tothoseofnor-
mal group (Figure 1(a)). Cotreatment with SJDBT extract at
concentrations of 0.3–0.5mg/mL enhanced levels of cell sur-
vivalhigherthan80%.However,SJDBTextractat1.0mg/mL
slightly decreased cell survival. Thus, SJDBT extract at 0.3–
0.5mg/mL was used for the rest of the present study. To
determinewhetherapoptoticsignalingpathwaywasinvolved
in Aβ-induced cell death, caspase 3 activation was measured
in PC12 cells. Caspase 3 protein signals, which were not
detectedinintactPC12cells,wereinducedinsomeoftheAβ-
treatedcells(Figure 1(b)).Itwasobservedthatcaspase3pro-
tein signals were not localized at the central area where the
nucleus was identiﬁed by Hoechst staining. In cells treated
with SJDBT at 0.3mg/mL, caspase 3 signals were observed in
less cells compared to those in Aβ-treated cells. Furthermore,
in cells treated with Aβ and 0.5mg/mL of SJDBT, caspase 3
signals were not detected in any of cultured cells.
Eﬀects of SJDBT on morphological changes in Aβ-
treated PC12 cells were investigated. In NGF-treated PC12
cells, the cell body showed a morphology of spreading
and round shapes, and neurite processes were clearly
observed (Figure 2(a)). However, cells treated with Aβ
revealed shrunken cell body with no clear neurite processes.
When the cells were treated with SJDBT extract, neurite
growth processes were observed, and particularly longer
processes were frequently observed with SJDBT treatment at
0.5mg/mL. To further examine the pattern of neurite out-
growth, cells were subjected to immunoﬂuorescence staining
with anti-NF-200 antibody. While some neurite growth
processes were observed in NF-200-stained normal cells, Aβ
treatment resulted in overall weak NF-200 staining in PC12
cells with no clear neurite processes. SJDBT treatment at
0.3mg/mL strongly induced NF-200 staining in cultured
cells and showed distinct neurite processes (Figure 2(b)).
Longer extension of neurite processes were observed with
0.5mg/mLofSJDBTextractthoughoverallstainingintensity
was decreased compared to those treated with 0.3mg/mL of
SJDBT.
3.2.EﬀectsofSJDBTonCorticalNeuronsTreatedwithAβ Pep-
tide. To determine possible neuroprotective eﬀects of SJDBT
on Aβ-treated cerebral cortical neurons, levels of caspase 3
protein were analyzed. As shown in Figure 3(a), caspase 3
signals were not detected in normal tissue. Then, caspase 3-
positivesignalswereidentiﬁedinthebraintissuetreatedwith
Aβ peptide though the signals were limited to a few numbers
of the cells. Treatment of SJDBT or galantamine as a positive4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Cell death analysis of PC12 cells. PC12 cells were cultured in the presence of NGF (50ng/mL) at least for 7 days, and cells were
further treated with Aβ in the presence or the absence of SJDBT extract (0.3mg/mL or 0.5mg/mL) for 24hrs. (a) MTT assay. A549 cells were
incubated with Aβ (10μM) alone or in the presence of 0.3–1.0mg/mL of SJDBT extract. Cells were harvested 24hrs later for MTT assay. The
viabilityofPC12cellsisthepercentageofMTTvaluerelativetonormalcells.Mean ±standarderrorofmean(n = 3). ∗P<0.05, ∗∗P<0.01,
∗∗∗P<0.001 (one-way ANOVA). (b) Immunoﬂuorescence staining of PC12 cells with anticaspase 3 antibody (red) and Hoechst nuclear
staining (blue). All the images in (b) are shown as the merged ones of Hoechst nuclear staining and caspase 3 staining in PC12 cells.
Intact Aβ
Aβ + SJDBT (0.3 mg/mL) Aβ + SJDBT (0.5 mg/mL)
(a)
Intact Aβ
Aβ + SJDBT (0.3 mg/mL) Aβ +SJDBT (0.5 mg/mL)
(b)
Figure 2: Morphological features of PC12 cells after diﬀerent treatments. (a) Phase-contrast microscope of PC12 cells. (b) Neurite extension
of PC12 cells. Neurite growth processes were visualized by immunoﬂuorescence staining with anti-NF-200 antibodies (green). Neurite
extension was marked in arrows in the Figure.
control largely eliminated caspase 3 signals in the tissue
(Figure 3(a)). Merged immunoﬂuorescence view of caspase
3 protein signals with Hoechst-stained nuclei revealed that
caspase 3 signals were mostly found outside the nuclear area
(Figure 3(b)).
Morphological features of cerebral cortical neurons were
examined by visualizing neuronal processes with NF-200
immunostaining. It was noted that NF-200 staining intensity
in the cerebral cortex was higher in Aβ-a n dS J D B T -
treated groups compared to normal group. Yet, neuritic
processes were largely reduced in Aβ-treated group when
compared with intact control and galantamine or SJDBT-
treatedgroups.Extendedprocesseswerenotedparticularlyin
SJDBT-treated group (Figure 4(a)). It was further observed
that NF-200-stained neurite processes were labeled distinc-
tively with Hoechst-stained nuclear area (Figure 4(b)).Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Identiﬁcation of caspase 3-positive cells in the cerebral cortex. (a) Immunoﬂuorescence view of caspase 3 signals in the cerebral
cortex was seen in red. The sections were also stained with Hoechst33258 dye to visualize individual nuclei (blue). (b) Merged image of
caspase 3-positive signals with Hoechst-stained nuclei. The image was taken from the brain sections treated with Aβ peptide.
To determine whether SJDBT treatment aﬀects cell
survival, phospho-Erk1/2 protein levels, known to be upreg-
ulated in diverse cell types showing increased survival
activity, were investigated in the cerebral cortex of the rat
brain after diﬀerent treatments. Phospho-Erk1/2 protein was
clearly observed in the intact cortical area, but completely
abolished after Aβ treatment (Figure 5(a)). Galantamine
or SJDBT treatment induced phospho-Erk1/2 protein in
the cortical area, although its level was lower than that
in the intact tissue. Total Erk1/2 protein maintained at
constant levels in cortical tissues after diﬀerent treatments.
Immunoﬂuorescence staining showed that phospho-Erk1/2
protein signals were clearly observed in the intact cerebral
tissues. In Aβ-treated cortex, only a weak phospho-Erk1/2
protein signals were observed and increased in the tissues
treated with galantamine or SJDBT extract in addition to
Aβ (Figure 5(b)). Enlarged view of phospho-Erk1/2 signals
overlapped with NF-200 stained image showed distinct
subcellular localization; phospho-Erk1/2 signals were not
mostly overlapped with those of NF-200-stained processes
(Figure 5(c)).
4. Discussion
Although several transgenic mouse models of AD have been
developed and contributed to understanding AD pathology
[13–15], the major obstacles to study AD would be that
all of the experimental animals do not display the same
pattern of clinical symptoms that occur in AD patients [15].
Neuropathological features such as Aβ peptide deposition
in the senile plaque and blood vessels are commonly found
in aged primates such as chimpanzees and gorillas, but
histological properties including neuroﬁbrillary tangles and
neurite atrophy as well as behavioral AD symptoms are not
g e n e r a l l yo b s e r v e di nt h e s ea n i m a l sa so b s e r v e di nh u m a n s
[16]. Genetic mouse models in which mutated forms of
APP proteins are produced and accumulated in the brain
have been developed and widely used to understand at
least partial aspects of AD. Several lines of studies showed
that Aβ accumulation in the mouse brain was associated
with degeneration of the brain tissue and further linked
to behavioral learning abnormalities [17–19]. In addition,
animals with drugs such as interfering cholinergic neuronal
activities have been used for AD phenotypes [20].
Sibjeondaebo-tang (SJDBT),whichmeansadecoctionof
ten perfect tonifying drugs, was described in (DongEuySuSe-
BoWon) [9] and is known as one of the major tonifying and
replenishing therapies in Oriental medicine. Although there
arenorecordsofeﬃcacyorclinicalcases,itisconsideredthat
the chief virtue of SJDBT is similar to that of Palmigunja-
tang (PMGJT) [21, 22], in which the root of SJDBT is used
to manic syndrome of “Soeumin” person. Recent studies
further provide evidences that SJDBT and its herbal com-
ponents are eﬀective for treating diverse symptoms. Lee [9]
analyzed SJDBT prescriptions for the medical practitioners
of several generations and showed that SJDBT is applicable6 Evidence-Based Complementary and Alternative Medicine
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Aβ + Gal. Aβ + SJDBT
(a) (b)
Figure 4: Identiﬁcation of NF-200-positive cells in the cerebral cortex. (a) Immunoﬂuorescence view of NF-200 signals in the cerebral
cortex was seen in green. Notice that NF-200-stained neuronal processes were more intense in intact, galantamine or SJDBT-treated groups
compared to Aβ-treated group. (b) Merged view of NF-200-stained processes (green) with Hoechst-stained nuclei (blue). The image is the
representative from Aβ and SJDBT-treated group.
to treat Soeumin’s exterior symptoms. Moreover, principal
eﬃcacies of herbal components comprising SJDBT have
been described elsewhere [23], and there is an increasing
number of experimental studies on SJDBT [12, 24–26]; one
recent report suggested that SJDBT might participate in the
improvement of declined energy production and cholinergic
neurotransmitter synthesis in the mouse cerebral cortex
with memory loss [12], which is consistent with classical
hypothesis on SJDBT eﬃcacy. Another study suggested
that SJDBT might protect the spontaneous and glutamate-
induced neuronal damages in cultured cerebrocortical cells
of mouse [26].
Based on previous studies and classical descriptions, we
hypothesized that SJDBT might play a protective role for
neuronal cells in vitro as well as mouse brain in vivo.A s
the ﬁrst step to determine whether Aβ peptide has any toxic
eﬀect on cultured PC12 cells, Aβ-treated PC12 cells were
examined by MTT assay, morphology assay, and survival
assay. MTT assay showed clear decreases in cell viability.
Furthermore, investigation of cell morphology by Hoechst-
stained nucleus and phase-contrast microscopic analysis
showed shrunken cell body shape. Aβ treatment induced
caspase 3 protein signals in some PC12 cells, suggesting that
Aβ treatment might activate both apoptosis and necrotic cell
death pathways, as it has been implicated before [8, 27].
Besides the activation of cell death machinery, Aβ caused
decreased neurite extension in NGF-treated PC12 cells.
When Aβ-treated PC12 cells were cotreated with
0.3mg/mL or 0.5mg/mL of SJDBT extract, a few changes
were noted. Cell viability as determined by MTT assay and
a pattern of neurite extension were improved to the levels
similar to normal cells. Then, SJDBT treatment reduced the
number of caspase 3-positive cells. However, it should be
noted that caspase 3-positive cells by Aβ treatment were
very limited, while cell death proﬁle as determined by MTT
assay was much more noticeable. This implicates that both
apoptotic and necrotic death pathways are involved in Aβ-
mediated cell death, but the necrotic pathway may play
a major role in cell toxicity in PC12 cells. Based on the
protective eﬀects of SJDBT on Aβ-treated PC12 cells, similar
eﬀects by SJDBT extract were further examined in cerebral
cortical neurons in the rats. Aβ injection into the lateral
ventricle caused increased signals of caspase 3-positive cells
in the cerebral cortex, although caspase 3-positive signals
were limited to only a few numbers of cells. Caspase 3-
positive cells were scattered throughout the cortical area,
implicating homogeneity in Aβ toxicity to cortical neurons.
Oral administration of SJDBT extract into the mice caused
decreased levels of caspase 3-positive cells in the cerebral
cortex, suggesting the possible inhibitory activity of SJDBT
on apoptosis.
When the morphological features of Aβ-treated indi-
vidual cells were compared between cultured PC12 cells
and in vivo cortical neurons, cytotoxicity appears to be
much more severe to PC12 cells than in vivo neurons.
For instance, NF-200-stained neurons or Hoechst-stained
nuclei in vivo did not show any distinctive diﬀerences
among brain tissue after diﬀerent treatments, whereas the
shrinkage of PC12 cell bodies was generally observed after
Aβ treatment. Despite mild morphological eﬀects of Aβ
peptide on brain tissue in vivo,A β-induced changes in
molecular targets in relation to cell survival or death were
observed. Levels of phospho-Erk1/2 protein, a signal for
survival [28], were remarkably decreased by Aβ treatment
in cortical region and recovered by galantamine or SJDBT
treatment. Immunoﬂuorescence staining analysis showedEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: Induction of phospho-Erk1/2 in the cerebral cortex. (a) Western blot analysis. After various treatments into mice, cerebral cortical
tissuesweredissectedoutandusedforwesternblotanalysis.WesternanalysisfortotalErk1/2proteinforthesametransferredmembranewas
used as an internal loading control. 1: normal, 2: Aβ (200pmol/5μL ) ,3 :A β+galantamine (3 mg/kg), and 4: Aβ+SJDBT extract (400mg/kg),
(b, c). Immunoﬂuorescence staining of brain sections. (b) Brain sections were used for double immunoﬂuorescence staining for NF-200
protein (green) and phospho-Erk1/2 protein (red), and the merged images were shown in the ﬁgure. (c) Immunoﬂuorescence view of
phospho-Erk1/2proteinsignals(red)inNF-200-stainedcorticalsections(green).Mergedviewindicatesthattheareawherephospho-Erk1/2
signals are relatively strong is the central zone surrounded by NF-200-stained processes (arrowheads).
that phospho-Erk1/2 signals were largely localized in the cell
body region, particularly at the nuclear area. Since one of
the major downstream targets of phospho-Erk1/2 activity is
the transcription factors such as cAMP responsive element
binding protein (CREB), phospho-Erk1/2 could function
mostly in the nucleus besides cytoplasm.
5. Conclusions
Our experimental study provided evidence that SJDBT
extract can regulate molecular targets in the cell and induce
neuroprotective pathways in vivo as well as in vitro systems.
Since SJDBT is a mixture of several herbal ingredients, it is
reasonable to state that diverse chemicals comprising SJDBT
might interact with numerous cellular targets given Aβ-
induced toxicity. It should be also mentioned that while
SJDBT appears to protect neuronal cells, whether SJDBT
improves behavioral abnormality in association with AD
pathology remains to be explored. It is critical to develop
more convincing animal model representing neurological
characteristic of AD. By combining diverse principles and
technical applications, more speciﬁc and precise examina-
tions on the eﬃcacy of SJDBT would be possible.
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